MOTE Therapeutics Appoints MaryJane Rafii to Accelerate RNA Delivery Solution Expansion

MOTE Therapeutics Strengthens Leadership with MaryJane Rafii's Appointment



MOTE Therapeutics, a pioneering seed-stage biotechnology firm, has recently announced a significant addition to its leadership team. Dr. MaryJane Rafii, an expert in business development and capital strategy, will take on the role of Chief Investment and Business Officer. This strategic move is designed to propel the company’s global growth and enhance its RNA delivery solutions, particularly through its innovative MOBILIZE platform.

Who is MaryJane Rafii?


Dr. Rafii brings over 15 years of international experience in business development (BD) and fundraising to MOTE. Her expertise spans across multiple markets including the U.S., Europe, Asia, and the UAE, making her a valuable asset for the company as it aims to secure funding and establish partnerships. Rafii has a commendable background in scaling biotechnology platforms through effective capital strategies and strategic alliances.

Roc Cui, Chairman of Fapon and Co-Founder of MOTE, highlighted the significant impact Dr. Rafii's appointment will have on the company, stating, "MaryJane brings a strong track record of scaling biotech platforms through smart capital and strategic alliances. She's joining at a pivotal time in our trajectory."

Overview of MOTE Therapeutics


Founded by the Fapon Group and Dr. Wesselhoeft (from Orna Therapeutics), MOTE Therapeutics is on a mission to address one of the most critical challenges in RNA delivery: achieving effective cell-specific delivery beyond the liver. The MOBILIZE platform exemplifies MOTE's innovative approach, utilizing a modular liposomal nanoparticle (LNP) system that is designed for the purpose of targeted RNA delivery.

This platform stands out due to its unique bifunctional binder system, which allows for rapid, mix-and-go assembly of targeted nanoparticles without the need for chemical conjugation. This technology is crucial in enabling MOTE to deliver complex RNA payloads, including circular RNA (circRNA), to a variety of cell types, expanding the therapeutic potential for treating numerous diseases.

Recent Advances and Pipeline Prospects


MOTE has made significant strides in preclinical studies, demonstrating impressive results. These include an 80% reduction in liver uptake, allowing for targeting beyond the liver, as well as approximately 30% generation of CAR+ CD8+ T-cells from a low single dosage in non-human primates (NHPs). Moreover, advancements have shown successful B-cell depletion via in vivo CAR-T in NHPs and progress in blood-brain barrier (BBB) crossing delivery in CNS murine models.

To support its ambitious goals, MOTE is actively seeking to raise over $40 million in Series A funding. This capital will be pivotal in advancing their Investigational New Drug (IND)-enabling work for in vivo CAR-T programs, which are aimed at combating autoimmunity and hematologic cancers. Notably, Investigator Initiated Trials (IITs) are projected to commence in China in the latter half of 2025, further broadening MOTE's clinical reach.

Commitment to Innovation and Collaboration


“We’re inviting partners to join us in pushing the boundaries of RNA medicine. This is a delivery platform built to scale, with real data and broad applicability,” expressed Rafii, emphasizing the collaborative potential of MOTE’s pipeline and technology.

MOTE Therapeutics' focus on leveraging innovative RNA delivery mechanisms to target previously hard-to-reach cell types sets it apart in the biotech landscape. As the company aligns itself for growth under Dr. Rafii's guidance, MOTE aims to redefine the possibilities of RNA therapeutics, addressing crucial health challenges such as systemic lupus erythematosus, multiple myeloma, and various neurodegenerative diseases, among others.

About MOTE Therapeutics and Fapon


MOTE Therapeutics stands at the forefront of RNA medicinal advancements, aspiring to eliminate critical bottlenecks in nucleic acid medicine delivery. The firm benefits from the backing of the Fapon Group, a leader in life sciences providing integrated solutions for diagnostics and biopharma. With a robust global footprint, Fapon supports essential advancements in therapeutics technologies and artificial intelligence platforms, contributing to improved health outcomes worldwide.

This combination of innovative technology and impactful leadership positions MOTE Therapeutics to make significant contributions to RNA medicine as it pursues its mission in the international biotech arena.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.